MedTrace Logo

Risk of Reactivation of Occult Hepatitis B in Cancer Patients During Immunotherapy.

NCT06347588 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2025-12-24

No results posted yet for this study

Summary

The goal of this observational study is to evalue the cumulative proportion of patients with OBI who do not develop HBsAg seroreversion and/or an increase of serum HBV DNA by at least 1 log above the lower limit of detection of the assay in a patient who had previously undetectable HBsAg and HBV DNA in serum during the study.

Conditions

  • Occult Hepatitis B Infection in Cancer Patients

Interventions

OTHER

Observational: Blood sample of HVB-specific Elispot assay, HBSAg, HBV-DNA

Blood sample at baseline, week 4, month 3, 6, 9,12.

Sponsors & Collaborators

  • Fondazione IRCCS Policlinico San Matteo di Pavia

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-06
Primary Completion
2026-05-31
Completion
2026-12-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06347588 on ClinicalTrials.gov